{"id":"suvemcitug-injection-trifluridine-tipiracil-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL5315039","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Trifluridine is a thymidine-based nucleoside analog that is incorporated into DNA and inhibits thymidylate synthase, disrupting DNA synthesis. Tipiracil is a thymidine phosphorylase inhibitor that enhances trifluridine bioavailability by preventing its degradation. Together, they increase intracellular trifluridine concentrations, leading to DNA damage and cancer cell death.","oneSentence":"Trifluridine/tipiracil is a nucleoside analog combination that inhibits thymidylate synthase and incorporates into DNA to induce apoptosis in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:53:44.658Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (previously treated)"},{"name":"Gastric cancer (advanced or metastatic)"}]},"trialDetails":[{"nctId":"NCT07361003","phase":"PHASE3","title":"A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2025-11-12","conditions":"Refractory Metastatic Colorectal Cancer","enrollment":464}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Suvemcitug injection, trifluridine/tipiracil tablets","genericName":"Suvemcitug injection, trifluridine/tipiracil tablets","companyName":"Jiangsu Simcere Pharmaceutical Co., Ltd.","companyId":"jiangsu-simcere-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Trifluridine/tipiracil is a nucleoside analog combination that inhibits thymidylate synthase and incorporates into DNA to induce apoptosis in cancer cells. Used for Metastatic colorectal cancer (previously treated), Gastric cancer (advanced or metastatic).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}